Target Audience
This activity is intended for Primary Care Physicians, Physician Assistants, Registered Nurses, Nurse Practitioners, and other Allied Health professionals interested in the treatment of asthma.
Goals and Objectives
At the conclusion of this activity, the participant should be able to:
- Discuss the importance of inhaled corticosteroids in the management of asthma
- Recognize when to step up or step down therapy
- Describe the various therapeutic options when one needs to step up therapy
- Explain the biological effects of each agent and its role in treatment.
- Identify which patients are good candidates for the various options.
Accreditation
National Jewish Medical and Research Center is accredited by the ACCME to provide Continuing Medical Education for physicians.
National Jewish designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.
This activity has been reviewed and is acceptable for up to 2 prescribed credits by the American Academy of Family Physicians. Of these credits, 1 conforms to the AAFP criteria for evidence-based CME clinical content. CME credit has been increased to reflect 2 for 1 credit for only the EB CME portion. AAFP accreditation begins 08/01/07. The term of approval is for one year from this date, with option for yearly renewal. When reporting AAFP credit, report total Prescribed and Elective credit for this activity. It is not necessary to label credit as evidence based CME for reporting purposes.
Participating Faculty
Stanley J. Szefler, MD
Helen Wohlberg & Herman Lambert Chair in Pharmacokinetics
Head, Divisions of Pediatric Clinical Pharmacology, Department of Pediatrics
National Jewish Medical and Research Center
Professor of Pediatrics and Pharmacology
University of Colorado Health Science Center, Denver, Colorado
Leonard Fromer, MD, FAAFP
Assistant Clinical Professor Department of Family Medicine
University of California, Los Angeles Los Angeles, California
Richard J. Martin, MD, Program Chair
Chairman, Department of Medicine
National Jewish Medical and Research Center
Edelstein Family Chair in Pulmonary Medicine Professor of Medicine
National Jewish Medical and Research Center
University of Colorado Health Sciences Center Denver, Colorado
Faculty Disclosure
All faculty in a position to control the content of this activity are expected to disclose any or no significant financial interest or other relationship with any proprietary entity producing health care goods or services, with the exemption of non-profit or governmental organizations and non-health care related companies. Our goal is to ensure that there is no compromise of the ethical relationship that exists between those in a position to control the content of the activity and those attending the activity and their respective professional duties.
Significant financial interest is defined as receiving, or in the past twelve months having received, a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit.
KEY
| # Grant Support |
~ Speaker's Bureau |
| ^ Consultant |
> Other |
David Beuther, MD
# Merck & Co., Inc.
Ronina Covar, MD
^ AstraZeneca, Merck & Co., Inc.
# AstraZeneca, Ross Products/Abbott Laboratories
Stephen K. Frankel, MD
Has no significant financial interest to report
Leonard Fromer, MD
Has no significant financial interest to report
Richard Martin, MD
^ # ~ Altana, GlaxoSmithKline, Teva
^ ~ AstraZeneca, Genentech, Merck, Novartis, sanofi aventis
^ KaloBios, EarlySense
Harold Nelson, MD
^ Curalogic, Dey Laboratories, Dynavax Technologies, Genentech, GlaxoSmithKline, Johnson & Johnson, Novartis, Schering-Plough (Integrated Therapeutics Group)
~ AstraZeneca, GlaxoSmithKline
# Boehringer, Clinical Therapeutics, Genentech, MediciNova, Inc., Sepracor, Inc., Novartis, Schering-Plough (Integrated Therapeutics Group), Teva Pharmaceutical Industries Ltd., Wyeth
Stanley Szefler, MD
^ AstraZeneca, Genentech, GlaxoSmithKline, Merck, Inc., Novartis, sanofi-aventis
Richard W. Weber, MD
^ AstraZeneca, Genentech/Novartis
~ AstraZeneca, Genentech/Novartis, GlaxoSmithKline
# Eli Lilly and Company, GlaxoSmithKline, MannKind Corporation, Pfizer, Inc.
Commercial Support
This program is supported by an unrestricted educational grant from Schering-Plough.
|
Adobe Acrobat Reader